RGC stock forecast, quote, news & analysis
Regencell Bioscience Holdings Ltd is a bioscience company focusing on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people’s immune systems... Show more
Why Regencell Bioscience (RGC) Stock Is Down -39% in the Last 30 Days
Key Takeaways
- Regencell Bioscience (RGC) shares fell roughly 39% over the trailing 30 days, from a closing price of $8.11 on October 14 to about $4.95.
- The decline followed a sharp mid-October speculative surge that briefly pushed the stock above $11 intraday before momentum reversed.
- A widened fiscal 2026 net loss of $11.7 million, zero product revenue, and an adverse auditor opinion on internal controls weighed on sentiment.
- Disclosure of a U.S. Department of Justice probe into trading in the company's shares added a significant regulatory overhang.
- Ongoing securities class-action litigation and analyst downgrades reinforced the negative bias during the period.
- For additional detail on valuation and estimates, review Regencell's Price Targets, Earnings, and Forecast pages.
- Explore Trending AI Robots to see automated strategies tracking this and other names.
Regencell Bioscience (RGC) Company Overview and Market Position
Regencell Bioscience Holdings Limited is an early-stage bioscience company headquartered in Hong Kong that focuses on the research, development, and commercialization of Traditional Chinese Medicine (TCM) for neurocognitive disorders, specifically Attention Deficit Hyperactivity Disorder (ADHD) and Autism Spectrum Disorder (ASD). Founded in 2014 and listed on the Nasdaq Capital Market in July 2021, the company is developing standardized liquid-based TCM formula candidates for ADHD and ASD patients.
Regencell remains pre-revenue, with no approved or commercialized products and no granted patents. Its research and development efforts center on efficacy trials conducted in Hong Kong, and the company has stated its intention to pursue regulatory approval from the Hong Kong Chinese Medicines Board before any potential commercialization. Investors follow the stock for its speculative exposure to the ADHD and ASD treatment market, but the company's lack of revenue, limited workforce, and reliance on external financing make it a high-risk, early-stage holding.
Regencell Bioscience (RGC) Stock Price Performance: Last 30 Days vs. Quarter
Over the trailing 30 days, RGC shares fell approximately 39%, declining from a closing price of $8.11 on October 14 to roughly $4.95. The decline was not linear: the stock climbed sharply in mid-October, reaching a closing high of $10.80 on October 21 and an intraday high above $11, before a rapid sell-off erased those gains. A single-day drop of more than 21% in late October marked the beginning of the unwind.
Over the trailing quarter, the picture is more muted but still volatile. RGC closed at $5.24 on August 13 and traded near $4.95 in mid-November, a decline of roughly 5% to 6%. That relatively modest net change masks a wide trading range, as the stock surged toward the $11 level in October before retreating. The shares remain well below their 52-week high, reflecting sustained selling pressure on a longer timeframe.
What Drove RGC Stock Price in the Last 30 Days
The sharp pullback was driven primarily by the company's fiscal 2026 annual report for the year ended June 30, 2026, released in early October. Regencell disclosed a wider net loss of $11.7 million, up from $3.58 million in the prior year, with no product-sales revenue. The filing also revealed an adverse auditor opinion on internal financial controls and confirmed an active U.S. Department of Justice probe into trading in the company's shares.
Compounding these issues, the report referenced a planned $500 million at-the-market equity program, which raised concerns about potential dilution for existing shareholders. These company-specific setbacks coincided with ongoing securities class-action lawsuits filed by multiple law firms in mid-2026 and with analyst downgrades, including a consensus "Sell" rating. After a speculative rally in mid-October, the combination of weak fundamentals, regulatory scrutiny, and litigation overhang triggered a sharp reversal as momentum-oriented investors exited the position.
What Drove RGC Stock Performance Over the Last Quarter
The broader three-month trend has been characterized by extreme volatility rather than a single directional move. Despite a net decline of roughly 5% to 6% over the quarter, the stock experienced a dramatic spike above $11 before collapsing back toward the $5 level. This pattern reflects the stock's low-float, speculative trading dynamics and heavy insider concentration, which can amplify price swings in both directions.
Underlying the volatility, the company's fundamentals remained weak throughout the quarter. Regencell continues to generate no revenue, reported a significantly widened annual loss, and carries substantial doubt about its ability to continue as a going concern. The unresolved securities litigation and the Department of Justice investigation have kept institutional capital cautious, while a registered direct offering completed in May 2026 at $20.30 per share highlighted the company's reliance on dilutive financing to fund operations.
Trending AI Robots
Tickeron's Trending AI Robots page curates a focused selection of top-performing automated trading strategies from a broader ecosystem of hundreds of AI trading bots that collectively track thousands of tickers. Only the most relevant and consistently strong bots are featured in this section, giving traders a streamlined way to discover quantitative approaches. The bots vary widely in strategy, holding timeframe, and performance metrics, from short-term momentum models to longer-term trend-following systems. For investors seeking a data-driven, rules-based alternative to discretionary trading, exploring this curated list can offer useful perspective on how automated systems are positioning across the market.
RGC Stock Forecast Drivers: What Investors Should Watch Next
Investors monitoring Regencell should track several key factors. First, any progress or setbacks on the Department of Justice investigation and the pending securities class-action litigation could materially affect sentiment. Second, the company's liquidity position and ability to secure additional financing remain critical, given its pre-revenue status and going-concern disclosure. Third, regulatory milestones with the Hong Kong Chinese Medicines Board and any advancement of its TCM formula candidates toward commercialization represent potential catalysts, though they carry substantial execution risk.
Additionally, the planned at-the-market equity program introduces ongoing dilution risk, while broader macro conditions and risk appetite for speculative, early-stage biotechnology names may continue to influence short-term trading. These factors should be evaluated alongside the company's widening losses and the absence of approved products before forming any investment view.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
RGC sees MACD Histogram just turned negative
RGC saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on October 26, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 36 instances where the indicator turned negative. In 34 of the 36 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 26, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on RGC as a result. In 80 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
RGC moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for RGC crossed bearishly below the 50-day moving average on November 05, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RGC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
RGC broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where RGC's RSI Oscillator exited the oversold zone, 25 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 12 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +7.46% 3-day Advance, the price is estimated to grow further. Considering data from situations where RGC advanced for three days, in 153 of 176 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.
The Aroon Indicator entered an Uptrend today. In 126 of 145 cases where RGC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 87%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 48 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 55 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: RGC's P/B Ratio (317.076) is very high in comparison to the industry average of (6.379). RGC's P/E Ratio (-606.863) is considerably lower than the industry average of (0.548). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (183.387).
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating fairly steady price growth. RGC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RGC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry PharmaceuticalsGeneric